We are no longer providing equity research on Vical VICL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Vical VICL has reported positive preclinical results from its H1N1 swine flu vaccine, but we will maintain our fair value estimate until
Vical VICL announced strong first-quarter results and a collaboration with the U.S. Navy on swine flu, or H1N1 influenza, Thursday
We are maintaining our fair value estimate for Vical VICL as its development progress remains on track. The firm burned through $7 million in cash during the fourth quarter and ended
On Friday, Vical VICL announced plans to restructure its operations. While this will reduce its near-term cash burn, we are holding firm to our fair
After running more valuation scenarios, we're returning our fair value uncertainty rating for Vical VICL to very high from extreme. Our fair value estimate remains unchanged. Our current valuation depends on Vical obtaining about
We're raising our fair value uncertainty rating for Vical VICL to extreme from very high to account for the stock market's recent volatility. Until we have a better sense of the firm's
We are putting Vical VICL under review. We will reassess our fair value uncertainty rating for the firm given its need to pursue dilutive activities at potentially unattractive prices. We will publish a new report shortly.
We're placing Vical VICL under review, as we think its declining share price could hamper its ability to raise capital at fair levels. The firm may have
Vical VICL announced promising results for its Phase I DNA vaccine for pandemic flu recently that could result in a new alternative to conventional